Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1988 Apr;93(4):893–901. doi: 10.1111/j.1476-5381.1988.tb11477.x

In vivo pharmacological studies with SK&F 94836, a potent inotrope/vasodilator with a sustained duration of action.

R W Gristwood 1, M B Comer 1, R J Eden 1, E M Taylor 1, J A Turner 1, M Wallduck 1, D A Owen 1
PMCID: PMC1853882  PMID: 3390657

Abstract

1. SK&F 94836 (racemate) was studied in vivo for its cardiovascular properties in cats and dogs. 2. In anaesthetized cats and dogs SK&F 94836 administered intravenously caused increases in left ventricular contractility and decreases in peripheral vascular resistance at similar doses, thus demonstrating the compound to be a mixed acting positive inotropic/vasodilator agent. 3. In conscious instrumented dogs SK&F 94836 was active via the oral as well as intravenous route. 4. The inodilator activity of SK&F 94836 in conscious and anaesthetized animals occurred in association with minimal changes in either blood pressure or heart rate. 5. Detailed studies carried out on anaesthetized cats indicated that SK&F 94836 caused a balanced dilatation of both resistance and capacitance blood vessels. 6. Haemodynamic studies in anaesthetized cats indicated that as a consequence of the inotropic/vasodilator actions, SK&F 94836 caused significant increases in cardiac output and stroke volume. 7. Detailed studies in anaesthetized dogs indicated that significant inodilator activity occurred in the absence of an increase in myocardial oxygen consumption. 8. The duration of action of SK&F 94836 was sustained following both i.v. and oral administration. 9. We conclude that SK&F 94836, as an orally active inotropic/vasodilator agent with a sustained duration in vivo, has potential utility in the treatment of congestive heart failure.

Full text

PDF
893

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alousi A. A., Canter J. M., Montenaro M. J., Fort D. J., Ferrari R. A. Cardiotonic activity of milrinone, a new and potent cardiac bipyridine, on the normal and failing heart of experimental animals. J Cardiovasc Pharmacol. 1983 Sep-Oct;5(5):792–803. doi: 10.1097/00005344-198309000-00014. [DOI] [PubMed] [Google Scholar]
  2. Arbogast R., Brandt C. M., Fincker J. L., Schechter P. J. Acute hemodynamic effects of piroximone (MDL 19,205) in patients with moderate congestive heart failure: comparison with sodium nitroprusside. J Cardiovasc Pharmacol. 1986 Jan-Feb;8(1):82–89. doi: 10.1097/00005344-198601000-00014. [DOI] [PubMed] [Google Scholar]
  3. Bristol J. A., Sircar I., Moos W. H., Evans D. B., Weishaar R. E. Cardiotonic agents. 1. 4,5-Dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3 (2H)-pyridazinones: novel positive inotropic agents for the treatment of congestive heart failure. J Med Chem. 1984 Sep;27(9):1099–1101. doi: 10.1021/jm00375a001. [DOI] [PubMed] [Google Scholar]
  4. Cohn J. N., Archibald D. G., Ziesche S., Franciosa J. A., Harston W. E., Tristani F. E., Dunkman W. B., Jacobs W., Francis G. S., Flohr K. H. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1986 Jun 12;314(24):1547–1552. doi: 10.1056/NEJM198606123142404. [DOI] [PubMed] [Google Scholar]
  5. FRY D. L. Physiologic recording by modern instruments with particular reference to pressure recording. Physiol Rev. 1960 Oct;40:753–788. doi: 10.1152/physrev.1960.40.4.753. [DOI] [PubMed] [Google Scholar]
  6. Fielden R., Owen D. A., Taylor E. M. Hypotensive and vasodilator actions of SK&F 24260, a new dihydropyridine derivative. Br J Pharmacol. 1974 Nov;52(3):323–332. doi: 10.1111/j.1476-5381.1974.tb08599.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. GLEASON W. L., BRAUNWALD E. Studies on the first derivative of the ventricular pressure pulse in man. J Clin Invest. 1962 Jan;41:80–91. doi: 10.1172/JCI104469. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Gristwood R. W., Eden R. J., Owen D. A., Taylor E. M. Pharmacological studies with SK&F 94120, a novel positive inotropic agent with vasodilator activity. J Pharm Pharmacol. 1986 Jun;38(6):452–459. doi: 10.1111/j.2042-7158.1986.tb04609.x. [DOI] [PubMed] [Google Scholar]
  9. Jafri S. M., Burlew B. S., Goldberg A. D., Rogers A., Goldstein S. Hemodynamic effects of a new type III phosphodiesterase inhibitor (CI-914) for congestive heart failure. Am J Cardiol. 1986 Feb 1;57(4):254–259. doi: 10.1016/0002-9149(86)90901-x. [DOI] [PubMed] [Google Scholar]
  10. Johnston B. M., Owen D. A. Tissue blood flow and distribution of cardiac output in cats: changes caused by intravenous infusions of histamine and histamine receptor agonists. Br J Pharmacol. 1977 Jun;60(2):173–180. doi: 10.1111/j.1476-5381.1977.tb07738.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Ono H., Ohara N., Hashimoto K. Effect of an antianginal drug, perhexiline, on myocardial oxygen consumption in anesthetized open-chest dogs compared with verapamil and glyceryl trinitrate. Jpn Circ J. 1982 Jun;46(6):559–567. doi: 10.1253/jcj.46.559. [DOI] [PubMed] [Google Scholar]
  12. Taylor E. M., Cameron D., Eden R. J., Fielden R., Owen D. A. Hemodynamic profile of a new antihypertensive agent D,L-3-[2-(3-t-butylamino-2-hydroxypropoxy)phenyl]-6-hydrazinopyridazine (SK&F 92657). J Cardiovasc Pharmacol. 1981 Mar-Apr;3(2):337–354. doi: 10.1097/00005344-198103000-00012. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES